Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

What happens inside you after eating? new study maps nutrient processing

NCT ID NCT05784506

Knowledge-focused Sponsor: Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study measured how the body handles different nutrients—sugar, protein, and fats—by giving 147 healthy adults various food tolerance tests. Researchers tracked changes in hormones and other substances in the blood to understand nutrient processing patterns. The goal is to learn how different foods affect metabolism, which could eventually help improve diets for people with conditions like obesity and diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help design better diets for people with metabolic disorders like obesity and diabetes.
What could go wrong
This is an observational study that only measures short-term responses; it does not test a treatment or provide direct health benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

147 people

The number who actually took part.

Started

Sep 2023

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Those who agree to participate in the study and sign informed consent. 2. Age between 20 and 65 year. 3. Fasting plasma glucose \< 7.0mmol/l, and 2-hour postprandial plasma glucose \< 11.1mmol/l. 4. BMI \> 18 kg/m2. Exclusion Criteria: 1. History of diabetes. 2. Pregnant or lactating women. 3. The subjects had not received oral/systemic corticosteroids for 7 consecutive days during the last 6 months. 4. Subjects were taking medication known to affect glucose metabolism. 5. Subjects who take strong inhibitors of cytochrome P450 (CYP)3A4/5, for example, ketoconazole, azanaway, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir and telithromycin. 6. Patients with either of the following characteristics of severe hepatic disease: i. Two consecutive abnormal hepatic function results during recent four weeks, with ALT or AST three times the upper limit of the institutions normal reference ranges. ii. Hepatic excretion dysfunction (eg. hyperbilirubinemia) and/or synthesis dysfunction, or other decompensated liver disease. iii. Acute viral hepatitis, autoimmune hepatitis, and alcoholic hepatitis 7. Patients with moderate and severe renal impairment, and end-stage renal disease (serum creatinine \> 194.5 mmol/L, or serum potassium \> 5.5 mmol/L). 8. New York Heart Association (NYHA) functional class III or IV congestive heart failure. 9. History of acute or chronic pancreatitis. 10. History of gastrointestinal disorders: gastroenterostomy, enterectomy, ileus and intestinal ulcers. 11. Subjects with previously diagnosed malignancy within the past 5 years. 12. Any other reasons that the investigator considered inappropriate to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolism disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic disease nutritional disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolism disorder Nutrition

Contacts and locations

Locations

  • First Affiliated Hospital, Nanjing Medical University

    Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.